Optinose US
Optinose US, Inc.
1020 Stony Hill Road,
Yardley,
PA 19067
Phone: (267) 364-3500Website: https://www.optinose.com
Latest news
- Xhance Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps
15 March 2024 - Optinose Announces FDA Approval of Xhance (fluticasone propionate) Nasal Spray for the Treatment of Nasal Polyps
19 September 2017 - OptiNose Announces FDA Acceptance for Filing of the New Drug Application for OPN-375
31 January 2017
Drugs Associated with Optinose US, Inc.
Optinose US, Inc. manufactures, markets and/or distributes 1 drug in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.
| Brand/Generic Name | Reviews | Rating |
|---|---|---|
|
Xhance
Generic name: fluticasone Drug class: nasal steroids |
23 reviews | 6.4 / 10 |
| For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective). | ||